Citations (130)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Zarrin Basharat & Alotaibi Meshal. (2023) Pan-genome mediated therapeutic target mining in Kingella kingae and inhibition assessment using traditional Chinese medicinal compounds: an informatics approach. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-14.
Read now
Read now
Amira M Ghoneim & Suzan M Mansour. (2020) The Effect of Liver and Kidney Disease on the Pharmacokinetics of Clozapine and Sildenafil: A Physiologically Based Pharmacokinetic Modeling. Drug Design, Development and Therapy 14, pages 1469-1479.
Read now
Read now
Verena Gotta, Kim Dao, Frédérique Rodieux, Thierry Buclin, Françoise Livio & Marc Pfister. (2017) Guidance to develop individual dose recommendations for patients on chronic hemodialysis. Expert Review of Clinical Pharmacology 10:7, pages 737-752.
Read now
Read now
Arduino A Mangoni & Alberto Pilotto. (2016) New drugs and patient-centred end-points in old age: setting the wheels in motion. Expert Review of Clinical Pharmacology 9:1, pages 81-89.
Read now
Read now
Eline W Muilwijk, Vincent JC Lempers, David M Burger, Adilia Warris, Peter Pickkers, Rob E Aarnoutse & Roger JM Brüggemann. (2015) Impact of special patient populations on the pharmacokinetics of echinocandins. Expert Review of Anti-infective Therapy 13:6, pages 799-815.
Read now
Read now
Karen Rowland Yeo, Masoud Jamei & Amin Rostami-Hodjegan. (2013) Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Review of Clinical Pharmacology 6:2, pages 143-157.
Read now
Read now
Articles from other publishers (124)
Hiroshi Komura, Reiko Watanabe & Kenji Mizuguchi. (2023) The Trends and Future Prospective of In Silico Models from the Viewpoint of ADME Evaluation in Drug Discovery. Pharmaceutics 15:11, pages 2619.
Crossref
Crossref
Ammara Zamir, Muhammad Fawad Rasool, Imran Imran, Hamid Saeed, Sundus Khalid, Abdul Majeed, Anees Ur Rehman, Tanveer Ahmad, Fawaz Alasmari & Faleh Alqahtani. (2023) Physiologically Based Pharmacokinetic Model To Predict Metoprolol Disposition in Healthy and Disease Populations. ACS Omega 8:32, pages 29302-29313.
Crossref
Crossref
Muhammad Talha Zahid, Ammara Zamir, Abdul Majeed, Imran Imran, Sary Alsanea, Tanveer Ahmad, Faleh Alqahtani & Muhammad Fawad Rasool. (2023) A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations. Saudi Pharmaceutical Journal 31:8, pages 101675.
Crossref
Crossref
Josephine A. Adattini, Jeffry Adiwidjaja, Annette S. Gross & Andrew J. McLachlan. (2023) Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia. Pharmacology Research & Perspectives 11:4.
Crossref
Crossref
Fawaz Alasmari, Mohammed S. Alasmari, Hussa Mubarak Muwainea, Hatun A. Alomar, Abdullah F. Alasmari, Sary Alsanea, Aws Alshamsan, Muhammad F. Rasool & Faleh Alqahtani. (2023) Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing. Frontiers in Pharmacology 14.
Crossref
Crossref
Karen Rowland Yeo, Oliver Hatley, Ben G. Small & Trevor N. Johnson. (2023) Physiologically Based Pharmacokinetic Modelling to Predict Imatinib Exposures in Cancer Patients with Renal Dysfunction: A Case Study. Pharmaceutics 15:7, pages 1922.
Crossref
Crossref
Mo'tasem M. Alsmadi & Saja B. Alzughoul. (2022)
In vitro–in vivo
extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapolation to human
. Biopharmaceutics & Drug Disposition 44:3, pages 221-244.
Crossref
Crossref
Faleh Alqahtani, Ali Mohammed Asiri, Ammara Zamir, Muhammad Fawad Rasool, Amer S. Alali, Sary Alsanea & Ismail A. Walbi. (2023) Predicting Hydroxychloroquine Clearance in Healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach. Pharmaceutics 15:4, pages 1250.
Crossref
Crossref
Wanhong Wu, Rongfang Lin, Meng Ke, Lingling Ye & Cuihong Lin. (2023) Physiologically Based Pharmacokinetic Modeling Characterizes the Drug‐Drug Interaction Between Saxagliptin and Rifampicin in Patients With Renal Impairment. The Journal of Clinical Pharmacology.
Crossref
Crossref
Mo’tasem M. Alsmadi. (2023) The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling. Drug Metabolism and Personalized Therapy 38:1, pages 87-105.
Crossref
Crossref
Jie Liu, Fan Yang, Yousuf Waheed, Shulin Li, Kun Liu & Xinglei Zhou. (2023) The role of roxadustat in chronic kidney disease patients complicated with anemia. The Korean Journal of Internal Medicine 38:2, pages 147-156.
Crossref
Crossref
Xinyi Wu, Jie En Valerie Sia, Min Hai, Xuan Lai, Haiyan Li, Cheng Cui & Dongyang Liu. (2023) Physiologically Based Pharmacokinetic Model for Older Adults and Its Application in
Geriatric Drug Research. Current Drug Metabolism 24:3, pages 211-222.
Crossref
Crossref
Sundus Khalid, Muhammad Fawad Rasool, Imran Masood, Imran Imran, Hamid Saeed, Tanveer Ahmad, Nawaf Shalih Alqahtani, Fahad Ali Alshammari & Faleh Alqahtani. (2023) Application of a physiologically based pharmacokinetic model in predicting captopril disposition in children with chronic kidney disease. Scientific Reports 13:1.
Crossref
Crossref
Saeed Alshahrani. (2023) Renin–angiotensin–aldosterone pathway modulators in chronic kidney disease: A comparative review. Frontiers in Pharmacology 14.
Crossref
Crossref
Vianney Tuloup, Sylvain Goutelle, Michel Tod & Laurent Bourguignon. (2023) Evaluation of Renal Impairment Influence on Metabolic Drug Clearance using a Modelling Approach. Clinical Pharmacokinetics 62:2, pages 307-319.
Crossref
Crossref
Ryuta Asaumi & Kiyohiko Sugano. 2023. Advances in Pharmacokinetics and Pharmacodynamics. Advances in Pharmacokinetics and Pharmacodynamics
3
27
.
Hafsa Hafsa, Ammara Zamir, Muhammad Fawad Rasool, Imran Imran, Hamid Saeed, Tanveer Ahmad, Sary Alsanea, Ali A. Alshamrani, Abdullah H. Alruwaili & Faleh Alqahtani. (2022) Development and Evaluation of a Physiologically Based Pharmacokinetic Model of Labetalol in Healthy and Diseased Populations. Pharmaceutics 14:11, pages 2362.
Crossref
Crossref
Mo'tasem M. Alsmadi, Laith N. AL Eitan, Nasir M. Idkaidek & Karem H. Alzoubi. (2022) The Development of a PBPK Model for Atomoxetine Using Levels in Plasma,
Saliva and Brain Extracellular Fluid in Patients with Normal and Deteriorated
Kidney Function. CNS & Neurological Disorders - Drug Targets 21:8, pages 704-716.
Crossref
Crossref
Jeffry Adiwidjaja, Josephine A. Adattini, Alan V. Boddy & Andrew J. McLachlan. (2022) Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS‐CoV‐2 Infection: A Case Study With Imatinib. The Journal of Clinical Pharmacology 62:10, pages 1285-1296.
Crossref
Crossref
Hiroyuki Takita, Daniel Scotcher, Xiaoyan Chu, Ka Lai Yee, Kayode Ogungbenro & Aleksandra Galetin. (2022)
Coproporphyrin I as an Endogenous Biomarker to Detect Reduced
OATP1B
Activity and Shift in Elimination Route in Chronic Kidney Disease
. Clinical Pharmacology & Therapeutics 112:3, pages 615-626.
Crossref
Crossref
Shawn Pei Feng Tan, Daniel Scotcher, Amin Rostami‐Hodjegan & Aleksandra Galetin. (2022) Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically‐Based Pharmacokinetic Modeling and Dose Adjustment. Clinical Pharmacology & Therapeutics 112:3, pages 643-652.
Crossref
Crossref
Mo’tasem M. Alsmadi, Nour M. AL-Daoud, Rana M. Obaidat & Niazy A. Abu-Farsakh. (2022) Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human. AAPS PharmSciTech 23:5.
Crossref
Crossref
Samuel Dubinsky, Paul Malik, Dagmar M. Hajducek & Andrea Edginton. (2022) Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics 61:7, pages 997-1012.
Crossref
Crossref
Felix Stader & Catia Marzolini. (2021) Sex-related pharmacokinetic differences with aging. European Geriatric Medicine 13:3, pages 559-565.
Crossref
Crossref
Matthew D. Harwood, Amin Rostami‐Hodjegan & Sibylle Neuhoff. 2022. Drug Transporters. Drug Transporters
475
496
.
Janna K. Duong, Romina A. Nand, Aarti Patel, Oscar Della Pasqua & Annette S. Gross. (2022) A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity. Pharmacology Research & Perspectives 10:2.
Crossref
Crossref
Daniel Scotcher & Aleksandra Galetin. (2021) PBPK Simulation-Based Evaluation of Ganciclovir Crystalluria Risk Factors: Effect of Renal Impairment, Old Age, and Low Fluid Intake. The AAPS Journal 24:1.
Crossref
Crossref
Thomas D. Nolin, Albert W. Dreisbach, Arthur J. AtkinsonJr.Jr. & Juan J.L. Lertora. 2022. Atkinson's Principles of Clinical Pharmacology. Atkinson's Principles of Clinical Pharmacology
61
72
.
Chang‑Keun Cho, Pureum Kang, Hye-Jung Park, Yun Jeong Lee, Jung‑Woo Bae, Choon-Gon Jang & Seok-Yong Lee. (2021) Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Archives of Pharmacal Research 44:11, pages 1037-1049.
Crossref
Crossref
Chen-Xi Lu, Xiao-Xiao An, Yichao Yu, Li-Rong Jiao, Daniele Canarutto, Guo-Fu Li & Guo Yu. (2021) Pooled Analysis of Gastric Emptying in Patients With Obesity: Implications for Oral Absorption Projection. Clinical Therapeutics 43:10, pages 1768-1788.
Crossref
Crossref
Paulien Ravenstijn, Manoranjenni Chetty & Pooja Manchandani. (2021) Design and conduct considerations for studies in patients with impaired renal function. Clinical and Translational Science 14:5, pages 1689-1704.
Crossref
Crossref
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
417
428
.
Chie Emoto, Trevor N. Johnson, Takaaki Yamada, Hiroshi Yamazaki & Tsuyoshi Fukuda. (2021) Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition. European Journal of Clinical Pharmacology 77:8, pages 1157-1168.
Crossref
Crossref
Tycho Heimbach, Yuan Chen, Jun Chen, Vaishali Dixit, Neil Parrott, Sheila Annie Peters, Italo Poggesi, Pradeep Sharma, Jan Snoeys, Mohamad Shebley, Guoying Tai, Susanna Tse, Vijay V. Upreti, Ying‐Hong Wang, Alice Tsai, Binfeng Xia, Ming Zheng, Andy Z.X. Zhu & Stephen Hall. (2020) Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective. Clinical Pharmacology & Therapeutics 110:2, pages 297-310.
Crossref
Crossref
Mo'tasem M. Alsmadi, Nour M AL‐Daoud, Mays M. Jaradat, Saja B. Alzughoul, Amani D. Abu Kwiak, Salam S. Abu Laila, Ayat J. Abu Shameh, Mohammad K. Alhazabreh, Sana'a A. Jaber & Hala T. Abu Kassab. (2021) Physiologically‐based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment. Biopharmaceutics & Drug Disposition 42:6, pages 263-284.
Crossref
Crossref
Sonja E. Zapke, Stefan Willmann, Scott-Oliver Grebe, Kristin Menke, Petra A. Thürmann & Sven Schmiedl. (2021) Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring. Frontiers in Pharmacology 12.
Crossref
Crossref
Sînziana Cristea, Elke H. J. Krekels, Karel Allegaert, Peter De Paepe, Annick de Jaeger, Pieter De Cock & Catherijne A. J. Knibbe. (2021) Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3. The AAPS Journal 23:3.
Crossref
Crossref
Lei Sun, Lisa von Moltke & Karen Rowland Yeo. (2020) Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination. Clinical Pharmacokinetics 60:5, pages 637-647.
Crossref
Crossref
Muhammad F. Rasool, Shazia Ali, Sundus Khalid, Ramsha Khalid, Abdul Majeed, Imran Imran, Hamid Saeed, Muhammad Usman, Mohsin Ali, Amer S. Alali, Abdullah F. AlAsmari, Nemat Ali, Ali Mohammed Asiri, Fawaz Alasmari & Faleh Alqahtani. (2021) Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases. Scientific Reports 11:1.
Crossref
Crossref
Felix Stader, Perrine Courlet, Hannah Kinvig, Manuel Battegay, Laurent A. Decosterd, Melissa A. Penny, Marco Siccardi & Catia Marzolini. (2020) Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. British Journal of Clinical Pharmacology 87:2, pages 458-470.
Crossref
Crossref
Bappaditya Chatterjee, Pinaki Sengupta & Rakesh Kumar Tekade. 2021. Biopharmaceutics and Pharmacokinetics Considerations. Biopharmaceutics and Pharmacokinetics Considerations
195
277
.
Dorien Groenendaal-van de Meent, Virginie Kerbusch, Rudiger Kaspera, Begona Barroso-Fernandez, Piergiorgio Galletti, Gernot K. Klein & Martin den Adel. (2020) Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. European Journal of Drug Metabolism and Pharmacokinetics 46:1, pages 141-153.
Crossref
Crossref
Cheng Cui, Xiaobei Li, Hao Liang, Zhe Hou, Siqi Tu, Zhongqi Dong, Xueting Yao, Miao Zhang, Xuan Zhang, Haiyan Li, Xiaocong Zuo & Dongyang Liu. (2021) Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients. Biopharmaceutics & Drug Disposition 42:1, pages 24-34.
Crossref
Crossref
Yoko Franchetti & Thomas D. Nolin. (2020) Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation. The Journal of Clinical Pharmacology 60:S1.
Crossref
Crossref
Paul R.V. Malik, Cindy H.T. Yeung, Shams Ismaeil, Urooj Advani, Sebastian Djie & Andrea N. Edginton. (2020) A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease. The Journal of Clinical Pharmacology 60:S1.
Crossref
Crossref
Karen Rowland Yeo, Mian Zhang, Xian Pan, Alice Ban Ke, Hannah M. Jones, David Wesche & Lisa M. Almond. (2020) Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling. Clinical Pharmacology & Therapeutics 108:5, pages 976-984.
Crossref
Crossref
Marilyn N. Martinez, Jonathan P. Mochel & Devendra Pade. (2020) Considerations in the extrapolation of drug toxicity between humans and dogs. Current Opinion in Toxicology 23-24, pages 98-105.
Crossref
Crossref
Weize Huang & Nina Isoherranen. (2020) Novel Mechanistic PBPK Model to Predict Renal Clearance in Varying Stages of CKD by Incorporating Tubular Adaptation and Dynamic Passive Reabsorption. CPT: Pharmacometrics & Systems Pharmacology 9:10, pages 571-583.
Crossref
Crossref
Santosh Kumar Puttrevu, Sumit Arora, Sebastian Polak & Nikunj Kumar Patel. (2020) Physiologically Based Pharmacokinetic Modeling of Transdermal Selegiline and Its Metabolites for the Evaluation of Disposition Differences between Healthy and Special Populations. Pharmaceutics 12:10, pages 942.
Crossref
Crossref
Sînziana Cristea, Elke Henriëtte Josephina Krekels, Amin Rostami-Hodjegan, Karel Allegaert & Catherijne Annette Jantine Knibbe. (2020) The Influence of Drug Properties and Ontogeny of Transporters on Pediatric Renal Clearance through Glomerular Filtration and Active Secretion: a Simulation-Based Study. The AAPS Journal 22:4.
Crossref
Crossref
Muhammad Fawad Rasool, Ramsha Khalid, Imran Imran, Abdul Majeed, Hamid Saeed, Fawaz Alasmari, Mohammed Mufadhe Alanazi & Faleh Alqahtani. (2020) Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach. Drug Metabolism and Disposition 48:7, pages 570-579.
Crossref
Crossref
Silvia M. Mihaila, João Faria, Maurice F. J. Stefens, Dimitrios Stamatialis, Marianne C. Verhaar, Karin G. F. Gerritsen & Rosalinde Masereeuw. (2020) Drugs Commonly Applied to Kidney Patients May Compromise Renal Tubular Uremic Toxins Excretion. Toxins 12:6, pages 391.
Crossref
Crossref
Lisa Alina Kneller & Georg Hempel. (2020) Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach. Pharmaceutical Research 37:6.
Crossref
Crossref
Kosuke Doki, Keisuke Kuga, Kazutaka Aonuma, Masaki Ieda & Masato Homma. (2020) Utilizing physiologically based pharmacokinetic modeling to predict theoretically conceivable extreme elevation of serum flecainide concentration in an anuric hemodialysis patient with cirrhosis. European Journal of Clinical Pharmacology 76:6, pages 821-831.
Crossref
Crossref
Kunal S. Taskar, Venkatesh Pilla Reddy, Howard Burt, Maria M. Posada, Manthena Varma, Ming Zheng, Mohammed Ullah, Arian Emami Riedmaier, Ken‐ichi Umehara, Jan Snoeys, Masanori Nakakariya, Xiaoyan Chu, Maud Beneton, Yuan Chen, Felix Huth, Rangaraj Narayanan, Dwaipayan Mukherjee, Vaishali Dixit, Yuichi Sugiyama & Sibylle Neuhoff. (2019) Physiologically‐Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations. Clinical Pharmacology & Therapeutics 107:5, pages 1082-1115.
Crossref
Crossref
Thomas M. Polasek & Amin Rostami‐Hodjegan. (2020) Virtual Twins: Understanding the Data Required for Model‐Informed Precision Dosing. Clinical Pharmacology & Therapeutics 107:4, pages 742-745.
Crossref
Crossref
Felix Stader, Hannah Kinvig, Melissa A. Penny, Manuel Battegay, Marco Siccardi & Catia Marzolini. (2019) Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. Clinical Pharmacokinetics 59:3, pages 383-401.
Crossref
Crossref
Weize Huang & Nina Isoherranen. (2020) Sampling Site Has a Critical Impact on Physiologically Based Pharmacokinetic Modeling. Journal of Pharmacology and Experimental Therapeutics 372:1, pages 30-45.
Crossref
Crossref
Stephanie N. Liu, Zeruesenay Desta & Brandon T. Gufford. (2019) Probenecid‐Boosted Tenofovir: A Physiologically‐Based Pharmacokinetic Model‐Informed Strategy for On‐Demand HIV Preexposure Prophylaxis. CPT: Pharmacometrics & Systems Pharmacology 9:1, pages 40-47.
Crossref
Crossref
Daniel Moj, Hugo Maas, André Schaeftlein, Nina Hanke, José David Gómez-Mantilla & Thorsten Lehr. (2019) A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients. Clinical Pharmacokinetics 58:12, pages 1577-1593.
Crossref
Crossref
Thomas K. van der MadeMichele Fedecostante, Daniel ScotcherAmin Rostami-HodjeganJavier Sastre Toraño, Igor Middel, Andries S. Koster, Karin G. Gerritsen, Vera Jankowski, Joachim Jankowski, Joost G. J. Hoenderop, Rosalinde Masereeuw & Aleksandra Galetin. (2019)
Quantitative Translation of Microfluidic Transporter
in Vitro
Data to
in Vivo
Reveals Impaired Albumin-Facilitated Indoxyl Sulfate Secretion in Chronic Kidney Disease
. Molecular Pharmaceutics 16:11, pages 4551-4562.
Crossref
Crossref
Felix Stader, Melissa A. Penny, Marco Siccardi & Catia Marzolini. (2019) A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab. CPT: Pharmacometrics & Systems Pharmacology 8:7, pages 444-459.
Crossref
Crossref
Chie Emoto, Trevor N. Johnson, David Hahn, Uwe Christians, Rita R. Alloway, Alexander A. Vinks & Tsuyoshi Fukuda. (2019) A Theoretical Physiologically‐Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition. CPT: Pharmacometrics & Systems Pharmacology 8:5, pages 273-284.
Crossref
Crossref
Shankar Lanke & Susan E. Shoaf. (2019) Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease. The Journal of Clinical Pharmacology 59:5, pages 763-770.
Crossref
Crossref
Kentaro Konishi, Tsuyoshi Minematsu, Yasuhisa Nagasaka & Kenji Tabata. (2019) Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. Biopharmaceutics & Drug Disposition 40:5-6, pages 176-187.
Crossref
Crossref
Ming‐Liang Tan, Ping Zhao, Lei Zhang, Yunn‐Fang Ho, Manthena V.S. Varma, Sibylle Neuhoff, Thomas D. Nolin, Aleksandra Galetin & Shiew‐Mei Huang. (2018)
Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic
CYP
2C8 and
OATP
1B Drug Substrates
. Clinical Pharmacology & Therapeutics 105:3, pages 719-729.
Crossref
Crossref
Chun Yang, Dongmei Zhou, Zancong Shen, David M. Wilson, Matthew Renner, Jeffrey N. Miner, Jean-Luc Girardet & Caroline A. Lee. (2019) Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers. Drug Metabolism and Disposition 47:2, pages 104-113.
Crossref
Crossref
Violeta Balbas-Martinez, Robin Michelet, Andrea N. Edginton, Kevin Meesters, Iñaki F. Trocóniz & An Vermeulen. (2019) Physiologically-Based Pharmacokinetic model for Ciprofloxacin in children with complicated Urinary Tract Infection. European Journal of Pharmaceutical Sciences 128, pages 171-179.
Crossref
Crossref
Paula C. Zimbrean, Jennifer Braverman & Marta Novak. 2019. Psychosocial Care of End-Stage Organ Disease and Transplant Patients. Psychosocial Care of End-Stage Organ Disease and Transplant Patients
73
89
.
Manoranjenni Chetty, Trevor N. Johnson, Sebastian Polak, Farzaneh Salem, Kosuke Doki & Amin Rostami-Hodjegan. (2018) Physiologically based pharmacokinetic modelling to guide drug delivery in older people. Advanced Drug Delivery Reviews 135, pages 85-96.
Crossref
Crossref
Flavia Storelli, Caroline Samer, Jean-Luc Reny, Jules Desmeules & Youssef Daali. (2018) Complex Drug–Drug–Gene–Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives. Clinical Pharmacokinetics 57:10, pages 1267-1293.
Crossref
Crossref
Tom N. Lea-Henry, Jane E. Carland, Sophie L. Stocker, Jacob Sevastos & Darren M. Roberts. (2018) Clinical Pharmacokinetics in Kidney Disease. Clinical Journal of the American Society of Nephrology 13:7, pages 1085-1095.
Crossref
Crossref
Mohamad Shebley, Punam Sandhu, Arian Emami Riedmaier, Masoud Jamei, Rangaraj Narayanan, Aarti Patel, Sheila Annie Peters, Venkatesh Pilla Reddy, Ming Zheng, Loeckie de Zwart, Maud Beneton, Francois Bouzom, Jun Chen, Yuan Chen, Yumi Cleary, Christiane Collins, Gemma L. Dickinson, Nassim Djebli, Heidi J. Einolf, Iain Gardner, Felix Huth, Faraz Kazmi, Feras Khalil, Jing Lin, Aleksandrs Odinecs, Chirag Patel, Haojing Rong, Edgar Schuck, Pradeep Sharma, Shu-Pei Wu, Yang Xu, Shinji Yamazaki, Kenta Yoshida & Malcolm Rowland. (2018) Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective. Clinical Pharmacology & Therapeutics 104:1, pages 88-110.
Crossref
Crossref
Ming‐Liang Tan, Kenta Yoshida, Ping Zhao, Lei Zhang, Thomas D. Nolin, Micheline Piquette‐Miller, Aleksandra Galetin & Shiew‐Mei Huang. (2017) Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. Clinical Pharmacology & Therapeutics 103:5, pages 854-867.
Crossref
Crossref
Elisa Borella, Italo Poggesi & Paolo Magni. (2017) Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs. Clinical Pharmacokinetics 57:4, pages 505-514.
Crossref
Crossref
Ka Lai Yee, Mengyao Li, Tamara Cabalu, Vaishali Sahasrabudhe, Jian Lin, Ping Zhao & Pravin Jadhav. (2017) Evaluation of Model‐Based Prediction of Pharmacokinetics in the Renal Impairment Population. The Journal of Clinical Pharmacology 58:3, pages 364-376.
Crossref
Crossref
C-H Hsueh, V Hsu, P Zhao, L Zhang, KM Giacomini & S-M Huang. (2018) PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters. Clinical Pharmacology & Therapeutics 103:3, pages 485-492.
Crossref
Crossref
Amin Rostami-Hodjegan. (2018) Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence. Clinical Pharmacology & Therapeutics 103:2, pages 224-232.
Crossref
Crossref
Karol Jaroch, Alina Jaroch & Barbara Bojko. (2018) Cell cultures in drug discovery and development: The need of reliable in vitro-in vivo extrapolation for pharmacodynamics and pharmacokinetics assessment. Journal of Pharmaceutical and Biomedical Analysis 147, pages 297-312.
Crossref
Crossref
Pieter A. J. G. De Cock, Karel Allegaert, Matthew W. Linakis & Catherine M. T. Sherwin. 2018. Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill. Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill
239
263
.
Li Di, Christopher Breen, Rob Chambers, Sean T. Eckley, Robert Fricke, Avijit Ghosh, Paul Harradine, J. Cory Kalvass, Stacy Ho, Caroline A. Lee, Punit Marathe, Everett J. Perkins, Mark Qian, Susanna Tse, Zhengyin Yan & Maciej J. Zamek-Gliszczynski. (2017) Industry Perspective on Contemporary Protein-Binding Methodologies: Considerations for Regulatory Drug-Drug Interaction and Related Guidelines on Highly Bound Drugs. Journal of Pharmaceutical Sciences 106:12, pages 3442-3452.
Crossref
Crossref
Su-jin Rhee, Hyewon Chung, SoJeong Yi, Kyung-Sang Yu & Jae-Yong Chung. (2017) Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations. European Journal of Drug Metabolism and Pharmacokinetics 42:6, pages 973-980.
Crossref
Crossref
Weize Huang, Mariko Nakano, Jennifer Sager, Isabelle Ragueneau-Majlessi & Nina Isoherranen. (2017) Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions. Drug Metabolism and Disposition 45:11, pages 1156-1165.
Crossref
Crossref
Niloufar Marsousi, Jules A. Desmeules, Serge Rudaz & Youssef Daali. (2017) Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine. Journal of Pharmaceutical Sciences 106:9, pages 2380-2391.
Crossref
Crossref
Aleksandra Galetin, Ping Zhao & Shiew-Mei Huang. (2017) Physiologically Based Pharmacokinetic Modeling of Drug Transporters to Facilitate Individualized Dose Prediction. Journal of Pharmaceutical Sciences 106:9, pages 2204-2208.
Crossref
Crossref
JO Miners, X Yang, KM Knights & L Zhang. (2017) The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance. Clinical Pharmacology & Therapeutics 102:3, pages 436-449.
Crossref
Crossref
Jan Snoeys, Maria Beumont, Mario Monshouwer & Sivi Ouwerkerk-Mahadevan. (2016) Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics 56:7, pages 781-792.
Crossref
Crossref
Chiho Ono, Poe-Hirr Hsyu, Richat Abbas, Cho-Ming Loi & Shinji Yamazaki. (2017) Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug–Drug and Drug–Disease Interactions. Drug Metabolism and Disposition 45:4, pages 390-398.
Crossref
Crossref
Daniel Scotcher, Christopher R. Jones, Aleksandra Galetin & Amin Rostami-Hodjegan. (2017) Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations. Journal of Pharmacology and Experimental Therapeutics 360:3, pages 484-495.
Crossref
Crossref
Daniel Scotcher, Christopher Jones, Maria Posada, Aleksandra Galetin & Amin Rostami-Hodjegan. (2016) Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation. The AAPS Journal 18:5, pages 1082-1094.
Crossref
Crossref
Manjunath P. Pai. (2016) Anti-infective Dosing for Obese Adult Patients: A Focus on Newer Drugs to Treat Methicillin-resistant Staphylococcus aureus Acute Bacterial Skin and Skin Structure Infections. Clinical Therapeutics 38:9, pages 2032-2044.
Crossref
Crossref
K Yoshida, B Sun, L Zhang, P Zhao, DR Abernethy, TD Nolin, A Rostami‐Hodjegan, I Zineh & S‐M Huang. (2016) Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. Clinical Pharmacology & Therapeutics 100:1, pages 75-87.
Crossref
Crossref
May Almukainzi, Fakhreddin Jamali, Ali Aghazadeh-Habashi & Raimar Löbenberg. (2016) Disease specific modeling: Simulation of the pharmacokinetics of meloxicam and ibuprofen in disease state vs. healthy conditions. European Journal of Pharmaceutics and Biopharmaceutics 100, pages 77-84.
Crossref
Crossref
S. W. Johnny Lau & Raman K. Baweja. 2016. Developing Drug Products in an Aging Society. Developing Drug Products in an Aging Society
719
734
.
Manjunath P. Pai. 2016. Antibiotic Pharmacodynamics. Antibiotic Pharmacodynamics
599
620
.
Manjunath P Pai. (2015) Treatment of bacterial infections in obese adult patients: how to appropriately manage antimicrobial dosage. Current Opinion in Pharmacology 24, pages 12-17.
Crossref
Crossref
Muhammad Fawad Rasool, Feras Khalil & Stephanie Läer. (2015) A Physiologically Based Pharmacokinetic Drug–Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows. Clinical Pharmacokinetics 54:9, pages 943-962.
Crossref
Crossref
A Suri, S Chapel, C Lu & K Venkatakrishnan. (2015) Physiologically based and population PK modeling in optimizing drug development: A predict–learn–confirm analysis. Clinical Pharmacology & Therapeutics 98:3, pages 336-344.
Crossref
Crossref
Aki T. Heikkinen, Floriane Lignet, Paul Cutler & Neil Parrott. (2015) The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development. PROTEOMICS - Clinical Applications 9:7-8, pages 732-744.
Crossref
Crossref
Carolien Schophuizen, Joost Hoenderop, Rosalinde Masereeuw & Lambert Heuvel. (2015) Uremic Toxins Induce ET-1 Release by Human Proximal Tubule Cells, which Regulates Organic Cation Uptake Time-Dependently. Cells 4:3, pages 234-252.
Crossref
Crossref
Yoshinobu Nakamaru, Chie Emoto, Makiko Shimizu & Hiroshi Yamazaki. (2015) Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling. Biopharmaceutics & Drug Disposition 36:3, pages 148-162.
Crossref
Crossref
Oscar A. Linares, William E. Schiesser & Annemarie Daly. (2015) Organ-specific Microcirculatory Mass Transport of Oxycodone in Humans. The Clinical Journal of Pain 31:3, pages 206-213.
Crossref
Crossref
Michael A. Tortorici, David L. Cutler, Anasuya Hazra, Thomas D. Nolin, Karen Rowland-Yeo & Karthik Venkatakrishnan. (2015) Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease. The Journal of Clinical Pharmacology 55:3, pages 241-250.
Crossref
Crossref
Hiroyuki Sayama, Hiroaki Takubo, Hiroshi Komura, Motohiro Kogayu & Masahiro Iwaki. (2014) Application of a Physiologically Based Pharmacokinetic Model Informed by a Top-Down Approach for the Prediction of Pharmacokinetics in Chronic Kidney Disease Patients. The AAPS Journal 16:5, pages 1018-1028.
Crossref
Crossref
Marios Spanakis & Kostas Marias. (2014) In silico evaluation of gadofosveset pharmacokinetics in different population groups using the Simcyp® simulator platform. In Silico Pharmacology 2:1.
Crossref
Crossref
Maciej J. Zamek-Gliszczynski, Xiaoyan Chu, Joseph W. Polli, Mary F. Paine & Aleksandra Galetin. (2014) Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development. Drug Metabolism and Disposition 42:4, pages 650-664.
Crossref
Crossref
Hannah M. Jones & Neil Parrott. 2014. Predictive ADMET. Predictive ADMET
167
188
.
Sebastian Polak, Barbara Wiśniowska, Kamil Fijorek, Anna Glinka & Aleksander Mendyk. (2014) In vitro–in vivo extrapolation of drug-induced proarrhythmia predictions at the population level. Drug Discovery Today 19:3, pages 275-281.
Crossref
Crossref
Vicky Hsu, Manuela de L. T. Vieira, Ping Zhao, Lei Zhang, Jenny Huimin Zheng, Anna Nordmark, Eva Gil Berglund, Kathleen M. Giacomini & Shiew-Mei Huang. (2014) Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations. Clinical Pharmacokinetics 53:3, pages 283-293.
Crossref
Crossref
Winnie Vogt. (2013) Evaluation and Optimisation of Current Milrinone Prescribing for the Treatment and Prevention of Low Cardiac Output Syndrome in Paediatric Patients After Open Heart Surgery Using a Physiology-Based Pharmacokinetic Drug–Disease Model. Clinical Pharmacokinetics 53:1, pages 51-72.
Crossref
Crossref
Mark Donaldson. 2014. Nutrition and Oral Medicine. Nutrition and Oral Medicine
83
107
.
Carole E. Shardlow, Grant T. Generaux, Aarti H. Patel, Guoying Tai, Thuy Tran & Jackie C. Bloomer. (2013) Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development. Drug Metabolism and Disposition 41:12, pages 1994-2003.
Crossref
Crossref
Carolien M. S. Schophuizen, Martijn J. Wilmer, Jitske Jansen, Lena Gustavsson, Constanze Hilgendorf, Joost G. J. Hoenderop, Lambert P. van den Heuvel & Rosalinde Masereeuw. (2013) Cationic uremic toxins affect human renal proximal tubule cell functioning through interaction with the organic cation transporter. Pflügers Archiv - European Journal of Physiology 465:12, pages 1701-1714.
Crossref
Crossref
HM Jones & K Rowland‐Yeo. (2013) Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development. CPT: Pharmacometrics & Systems Pharmacology 2:8, pages 1-12.
Crossref
Crossref
Neil Parrott, Dominik Hainzl, Daniela Alberati, Carsten Hofmann, Richard Robson, Bruno Boutouyrie & Meret Martin-Facklam. (2013) Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin. Clinical Pharmacokinetics 52:8, pages 673-683.
Crossref
Crossref
Dietmar Schwab, Agnes Portron, Zoe Backholer, Berthold Lausecker & Kosuke Kawashima. (2013) A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant Intravenous Microdose Administration of [13C]Tofogliflozin in Humans. Clinical Pharmacokinetics 52:6, pages 463-473.
Crossref
Crossref
Hannah M. Jones, Kapil Mayawala & Patrick Poulin. (2012) Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches. The AAPS Journal 15:2, pages 377-387.
Crossref
Crossref
Frans G. M. Russel & Rosalinde Masereeuw. 2013. Transporters in Drug Development. Transporters in Drug Development
235
256
.
A Rostami-Hodjegan. (2012) Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology. Clinical Pharmacology & Therapeutics 92:1, pages 50-61.
Crossref
Crossref
Guillaume Baneyx, Yumi Fukushima & Neil Parrott. (2012) Use of physiologically based pharmacokinetic modeling for assessment of drug–drug interactions. Future Medicinal Chemistry 4:5, pages 681-693.
Crossref
Crossref
Joseph A. Grillo, Ping Zhao, Julie Bullock, Brian P. Booth, Min Lu, Kathy Robie‐Suh, Eva Gil Berglund, K. Sandy Pang, Atiqur Rahman, Lei Zhang, Lawrence J. Lesko & Shiew‐Mei Huang. (2012) Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharmaceutics & Drug Disposition 33:2, pages 99-110.
Crossref
Crossref
Assaf Gottlieb, Gideon Y Stein, Yoram Oron, Eytan Ruppin & Roded Sharan. (2012) INDI: a computational framework for inferring drug interactions and their associated recommendations. Molecular Systems Biology 8:1.
Crossref
Crossref
Arthur J. AtkinsonJr.Jr. & Juan J.L. Lertora. 2012. Principles of Clinical Pharmacology. Principles of Clinical Pharmacology
55
64
.
Masoud Jamei, Karen R. Yeo, Trevor N. Johnson, Cyrus Ghobadi, Manoranjenni Chetty, Khaled Abduljalil, Gaohua Lu, Farzaneh Salem, Adam Darwich & Amin Rostami-Hodjegan. 2012. Biosimulation in Biomedical Research, Health Care and Drug Development. Biosimulation in Biomedical Research, Health Care and Drug Development
361
386
.